The TriClip system, a first-in-class transcatheter edge-to-edge repair system, is safe and effective in reducing tricuspid regurgitation by at least one grade, according to findings from the TRILUMINATE study. The investigators in this prospective, multicentre, single-group study enrolled 85 patients with moderate or greater tricuspid regurgitation. The severity of tricuspid regurgitation was graded according to a five-class grading scheme. At 30 days after the procedure, 86% of 83 patients with echocardiogram data had a reduction in severity of tricuspid regurgitation by at least one grade (primary efficacy end point). At 6 months, the reduction in tricuspid regurgitation was associated with an improvement in right ventricular function. No cases of stroke, myocardial infarction or device embolization were observed during the study period. Randomized controlled trials are needed to assess the long-term outcomes associated with the TriClip system.